MRK Merck & Co.

Q3 2025 10-Q

Filed: Nov 5, 2025Period ending Sep 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Merck & Co. (MRK) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $17.3B Q3 2025, +4% YoY; $48.6B first 9 months 2025, flat YoY; oncology and diabetes drove growth, vaccines & virology declined
• Gross margin 77.7% Q3 2025 vs 75.5% YoY; 77.7% first 9 months 2025 vs 76.6% YoY; margin improvement from product mix and lower restructuring costs

+3 more insights

Risk Factors

• Section 'risk_factors' was empty or not found.

Quarterly Financial Summary
XBRL

Revenue

$17.3B

▲ +3.7% YoY▲ +9.3% QoQ

Net Income

$5.8B

▲ +83.2% YoY▲ +30.7% QoQ

Net Margin

33.5%

▲ +1453bp YoY▲ +548bp QoQ

ROE

11.2%

Total Assets

$129.5B

EPS (Diluted)

$2.31

▲ +86.3% YoY▲ +31.3% QoQ

Operating Cash Flow

$7.8B

▼ -15.8% YoY▲ +137.5% QoQ

Source: XBRL data from Merck & Co. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Merck & Co.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.